skip to content


GSK announces positive results from SLS lung study

11 September 2017 08:22

GlaxoSmithKline and Innoviva have announced that positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) International Congress in Milan.

The innovative study, which reported headline results in May 2017, showed that initiation of once-daily Relvar Ellipta (fluticasone furoate 'FF'/vilanterol 'VI' or 'FF/VI', called Breo Ellipta in the US) 92/22mcg or 184/22mcg was superior to usual care in achieving a consistent improvement in patient's asthma control over the 12 month study duration, measured by the Asthma Control Test (ACT), compared with patients who continued to take their usual care medicines.

Improvement was defined as an ACT total score ?20 or an increase from baseline of ?3. Statistically significant findings were also seen at 12, 40 and 52 weeks.

At 8:22am: (LON:GSK) GlaxoSmithKline PLC share price was +4.75p at 1498.75p

Story provided by

Related Company: GSK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg -

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.